Recent News
AffyImmune Therapeutics Announces Positive Safety and Early Efficacy Results from Phase 1 Study of AIC100 CAR T Cells in Anaplastic and Advanced Thyroid Cancers at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Data show unprecedented CAR T patient response in ICAM-1 positive relapsed and/or refractory advanced poorly differentiated and anaplastic thyroid cancers Of the two patients evaluable for efficacy assessment at day 42 treated with an intermediate dose of CAR T cells, both experienced tumor reductions, with one achieving a partial response [...]
AffyImmune Therapeutics Adds Serial Entrepreneur Robert Forrester to Board of Directors
NATICK, Mass. (SEPTEMBER 29, 2022) – AffyImmune Therapeutics, Inc., a clinical stage biotechnology company using its Tune & Track platform to develop CAR T cells for the treatment of solid cancers, announced today that serial biotech entrepreneur Robert Forrester has been appointed to its Board of Directors. Mr. Forrester’s biotech experience [...]
AffyImmune Therapeutics Announces Hiring of Dr. Sonal Gupta as Senior Vice President and Head of Clinical Development
NATICK, Mass. (APRIL 25, 2022) – AffyImmune Therapeutics, Inc., a clinical stage biotechnology company finding safe, effective ways to use CAR T cells against solid cancers, announced today the addition of Sonal Gupta, MD, PhD to its senior leadership team as Senior Vice President and Head of Clinical Development. “As immuno-oncology [...]
AffyImmune Therapeutics to Present Poster at American Association for Cancer Research Annual Meeting
NATICK, Mass. (APRIL 5, 2022) – AffyImmune Therapeutics, Inc., a clinical stage biotechnology company using its Tune & Track platform to develop CAR T cells for the treatment of solid cancers, announced today that it will present an abstract in a poster session at the 2022 American Association for Cancer Research [...]
AffyImmune Therapeutics Announces $30M Series A+ Financing from ORI Capital
NATICK, Mass., Oct. 7, 2021 /PRNewswire/ -- AffyImmune Therapeutics, Inc., a clinical stage biotechnology company developing and deploying its Tune & Track platform for the use of CAR T cells to treat solid tumors, announced today the close of a $30 million Series A+ funding by ORI Capital (ORI). The Company's [...]
AffyImmune Therapeutics to Present Initial Clinical Results at Upcoming CAR-TCR Summit
NATICK, Mass. (AUGUST 19, 2021) – AffyImmune Therapeutics, Inc., a clinical stage biotechnology company finding safe, effective ways to use CAR T cells against solid cancers, announced today that scientific co-founder Moonsoo Jin will present twice at Hanson Wade’s 6<sup>th</sup> CAR-TCR Summit being held virtually August 30 – September 2. [...]
Events
There are no events at this time.